ICH’s finalized M13B guideline sets a harmonized pathway for additional-strength biowaivers, with industry welcoming the potential to reduce duplicative bioequivalence studies while clarifying formulation and dissolution requirements.
ICH’s finalized M13B guideline sets a harmonized pathway for additional-strength biowaivers, with industry welcoming the potential to reduce duplicative bioequivalence studies while clarifying formulation and dissolution requirements.